naa a22 4500 510763812 CHVBK 20180411083149.0 cr unu---uuuuu 180411e20131001xx s 000 0 eng 10.1007/s12094-013-1009-1 doi (NATIONALLICENCE)springer-10.1007/s12094-013-1009-1 Expression and prognostic role of c-Myb as a novel cell cycle protein in esophageal squamous cell carcinoma [Elektronische Daten] [H. Lu, Y. Wang, Y. Huang, H. Shi, Q. Xue, S. Yang, S. He, H. Wang] Purpose: The c-Myb transcription factor controls differentiation and proliferation in hematopoietic and other cell types, and has latent in regulation during the cell cycle. Recent studies suggested that deregulation of c-Myb expression plays a key role in oncogenesis. To investigate the potential roles of c-Myb in esophageal carcinoma, expression of c-Myb was examined in human esophageal carcinoma samples. Methods: Immunohistochemistry and Western blot analysis were performed for c-Myb in 87 esophageal carcinoma samples. The data were correlated with clinicopathological features. The univariate and multivariate survival analyses were also performed to determine their prognostic significance. Results: c-Myb was overexpressed in esophageal carcinoma as compared with the adjacent normal tissue. High expression of c-Myb was associated with histological grade and was positively correlated with proliferation marker Ki-67 (P=0.001). Univariate analysis showed that c-Myb expression was associated with poor prognosis (P<0.001). Multivariate analysis indicated that c-Myb was an independent prognostic marker for esophageal carcinoma (P<0.001). While in vitro, following release from serum starvation of TE-1 esophageal carcinoma cell, the expression of c-Myb was upregulated. Conclusions: Our results suggested that c-Myb overexpression is involved in the pathogenesis of esophageal carcinoma; it may be a favorable independent poor prognostic parameter for esophageal carcinoma. Federación de Sociedades Españolas de Oncología (FESEO), 2013 c-Myb nationallicence Cyclin D1 nationallicence Esophageal squamous cell carcinoma nationallicence Proliferation nationallicence Lu H. Department of Cardiothoracic Surgery, Nantong University Cancer Hospital, Nantong University, 226001, Nantong, People's Republic of China aut Wang Y. Department of Cardiothoracic Surgery, Nantong University Cancer Hospital, Nantong University, 226001, Nantong, People's Republic of China aut Huang Y. Department of Cardiothoracic Surgery, Nantong University Cancer Hospital, Nantong University, 226001, Nantong, People's Republic of China aut Shi H. Department of Cardiothoracic Surgery, Nantong University Cancer Hospital, Nantong University, 226001, Nantong, People's Republic of China aut Xue Q. Department of Cardiothoracic Surgery, Nantong University Cancer Hospital, Nantong University, 226001, Nantong, People's Republic of China aut Yang S. Department of Cardiothoracic Surgery, Nantong University Cancer Hospital, Nantong University, 226001, Nantong, People's Republic of China aut He S. Department of Cardiothoracic Surgery, Nantong University Cancer Hospital, Nantong University, 226001, Nantong, People's Republic of China aut Wang H. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China aut Clinical and Translational Oncology Springer Milan 15/10(2013-10-01), 796-801 1699-048X 15:10<796 2013 15 12094 https://doi.org/10.1007/s12094-013-1009-1 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1009-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lu H. Department of Cardiothoracic Surgery, Nantong University Cancer Hospital, Nantong University, 226001, Nantong, People's Republic of China aut NATIONALLICENCE 700 1- Wang Y. Department of Cardiothoracic Surgery, Nantong University Cancer Hospital, Nantong University, 226001, Nantong, People's Republic of China aut NATIONALLICENCE 700 1- Huang Y. Department of Cardiothoracic Surgery, Nantong University Cancer Hospital, Nantong University, 226001, Nantong, People's Republic of China aut NATIONALLICENCE 700 1- Shi H. Department of Cardiothoracic Surgery, Nantong University Cancer Hospital, Nantong University, 226001, Nantong, People's Republic of China aut NATIONALLICENCE 700 1- Xue Q. Department of Cardiothoracic Surgery, Nantong University Cancer Hospital, Nantong University, 226001, Nantong, People's Republic of China aut NATIONALLICENCE 700 1- Yang S. Department of Cardiothoracic Surgery, Nantong University Cancer Hospital, Nantong University, 226001, Nantong, People's Republic of China aut NATIONALLICENCE 700 1- He S. Department of Cardiothoracic Surgery, Nantong University Cancer Hospital, Nantong University, 226001, Nantong, People's Republic of China aut NATIONALLICENCE 700 1- Wang H. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/10(2013-10-01), 796-801 1699-048X 15:10<796 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer